



Cell-Based Drugs in Cancer Immunotherapy

Guest Editor:

Dr. Urban Švajger

Department for Therapeutic
Services, Blood Transfusion
Centre of Slovenia, Ljubljana,
Slovenia

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editor

The development of Advanced Therapy Medicinal Products (ATMPs), particularly within the field of cellular therapies, is advancing at an astonishing rate. Cellular therapies are clearly becoming the next generation of pharmaceutical drugs and are already greatly complementing small molecules and biologicals. The first notable regulatory advance came in 2010, when Sipuleucel-T, a cell-based cancer immunotherapy, was approved by the FDA for the treatment of prostate cancer. The second major breakthrough both in a therapeutic and regulatory sense was the 2017 approval of tisagenlecleucel, a CAR-T cell therapy, for the treatment of B cell acute lymphoblastic leukemia. Since then, several ingenious approaches have been used to further advance the efficacy of cellular immunotherapy drugs by manipulating or engineering their major active substance, the living cell.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI